home / stock / edit / edit news

EDIT News and Press, Editas Medicine Inc. From 11/29/23

Stock Information
Company Name: Editas Medicine Inc.
Stock Symbol: EDIT
Market: NASDAQ
Website: editasmedicine.com
Menu
EDIT EDIT Quote EDIT Short EDIT News EDIT Articles EDIT Message Board
Get EDIT Alerts

News, Short Squeeze, Breakout and More Instantly...
EDIT - If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names

2023-11-29 14:28:48 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Some of the hottest opportunities can be found in biotech stocks . Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example. Since the start of...
EDIT - Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)

2023-11-28 14:36:05 ET Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - Head, Corporate Communications & IR Conference Call Participants Li...

EDIT - CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big

2023-11-25 03:39:49 ET Summary Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for its simplicity and versatility. Major publicly ...

EDIT - Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year

2023-11-22 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Nov. 25, 2022, I mentioned three stocks to buy that could soar in 2023. At the time, those included Advanced Micro Devices (NASDAQ: AMD ), which ran from $73 to $121.53; ...
EDIT - Gene editing stocks slide after two-day rally

2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...

EDIT - Gene editing stocks mixed despite world's first CRISPR drug approval

2023-11-16 15:54:01 ET More on CRISPR Therapeutics CRISPR Therapeutics: Positive Exa-Cel AdCom Opens Door For Historic Approval Risk And Reward: Evaluating Crispr's Exa-Cel For Sickle Cell Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A B...

EDIT - Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript)

2023-11-14 17:15:26 ET Editas Medicine, Inc. (EDIT) Stifel 2023 Healthcare Conference November 14, 2023 01:50 PM ET Company Participants Erick Lucera - EVP, CFO Cristi Barnett - VP, Corporate Communications and IR Conference Call Participants Dae Gon Ha -...
EDIT - Biotechs rally with gene editing stocks among notable gainers

2023-11-03 15:23:43 ET More on XBI and IBB Biopharma Bounce-Back: From Policy Pains To Profitable Plains IBB: The Illness Of Idiosyncratic Risk Jefferies is bullish on XBI at around $70 for year-end and first quarter 2024 returns Citi turns cautious on pharma...

EDIT - Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Call Transcript

2023-11-03 13:10:06 ET Editas Medicine, Inc. (EDIT) Q3 2023 Earnings Conference Call November 3, 2023, 8:00 am ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burk...

EDIT - Editas Medicine spikes after Q3 results

2023-11-03 10:23:43 ET More on Editas Medicine Editas Medicine: A Mispriced Contender In The Gene Editing Arena Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena Editas Medicine, Inc. (EDIT) Cantor Global Healthcare Conference 2023 - (Transcript) ...
Previous 10 Next 10